|FDA Clears the Focus Diagnostics Simplexa™ Flu A/B & RSV Direct Test to Include Eight Circulating Influenza Viruses|
|CYPRESS, Calif. and MADISON, N.J., Dec. 9, 2014 /PRNewswire/ -- As the 2014-2015 flu season begins, Focus Diagnostics, the products business of Quest Diagnostics (NYSE: DGX), today announced that its Simplexa™ Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter. The FDA, which granted 510(k) clearance to the test kit originally in July 2012, cleared additional ... ||12/09/14|
|Quest Diagnostics Declares Quarterly Cash Dividend|
|MADISON, N.J., Dec. 4, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.33 per share, payable on January 28, 2015 to shareholders of record of Quest Diagnostics common stock on January 13, 2015.
About Quest Diagnostics
Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to ma... ||12/04/14|
|Quest Diagnostics To Speak At The Piper Jaffray 26th Annual Healthcare Conference|
|MADISON, N.J., Dec. 1, 2014 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Piper Jaffray 26th Annual Healthcare Conference in New York City. Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, December 2, 2014 at 9:30 a.m. Eastern Time.
The presentation... ||12/01/14|
|Quest Diagnostics Discusses Progress in Executing Strategy to Drive Shareholder Value and Presents Outlook at Investor Day|
|- Company Expects to Generate 2% to 5% Revenue Growth and Adjusted Diluted EPS Growth of 8% to 10% on Average Over Next Three Years -
- New Target of $600 Million in Additional Run-Rate Savings Over Next Three Years Will Bring Total Run-Rate Savings Expected by End of 2017 to $1.3 billion -
NEW YORK, Nov. 5, 2014 /PRNewswire/ -- At a meeting with analysts and investors at its Investor Day here today, members of the senior management team of Quest Diagnostics Incorporated (NYSE: DGX), the... ||11/05/14|